<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144714</url>
  </required_header>
  <id_info>
    <org_study_id>SB5-G11-NHV</org_study_id>
    <secondary_id>2013-005332-15</secondary_id>
    <nct_id>NCT02144714</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects</brief_title>
  <official_title>A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira® and US Sourced Humira®) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics, safety, tolerability, and
      immunogenicity of SB5 and Humira (EU sourced Humira® and US sourced Humira®) in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>71 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>71 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)</measure>
    <time_frame>71 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>71 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">189</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB5, single dose of 40 mg via subcutaneous injection (study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU sourced Humira®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US sourced Humira®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US sourced Humira®, single dose of 40 mg via subcutaneous injection (reference drug)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB5</intervention_name>
    <arm_group_label>SB5</arm_group_label>
    <arm_group_label>EU sourced Humira®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU sourced Humira®</intervention_name>
    <arm_group_label>SB5</arm_group_label>
    <arm_group_label>US sourced Humira®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US sourced Humira®</intervention_name>
    <arm_group_label>EU sourced Humira®</arm_group_label>
    <arm_group_label>US sourced Humira®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Have a body mass index between 20.0 and 29.9 kg/m², inclusive.

        Exclusion Criteria:

          -  History and/or current presence of clinical significant atopic allergy,
             hypersensitivity or allergic reactions, also including known or suspected clinically
             relevant drug hypersensitivity to any components of the test and reference
             investigational product formulation or comparable drugs

          -  Active or latent Tuberculosis or who have a history of Tuberculosis

          -  History of invasive systemic fungal infections or other opportunistic infections

          -  Systemic or local infection, a known risk for developing sepsis and/or known active
             inflammatory process

          -  Serious infection associated with hospitalisation and/or which required intravenous
             antibiotics

          -  History of and/or current cardiac disease

          -  Have received live vaccine(s) within 4 weeks prior to Screening or who will require
             live vaccine(s) between Screening and the final study visit

          -  Intake medication with a half-life &gt; 24 h within 4 weeks or 10 half-lives of the
             medication prior to investigational product administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 11, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

